Antimicrobial Resistance Research Center, Mashhad University of Medical Science, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Immunol. 2023 Mar 14;20(1):76-82. doi: 10.22034/iji.2023.93812.2260.
Measuring the level of antibodies produced post-vaccination in response to the SARS-CoV-2 spike protein is considered a strategy for estimating the effectiveness of the COVID-19 vaccines.
To examine the antibody levels among the healthcare workers in different hospitals in Mashhad, Iran after receiving the second dose of Sputnik V.
In this study, we enrolled 230 healthcare workers for evaluating the Gam-COVID-Vac or Sputnik V after the second administration in different hospitals in Mashhad. Antibody levels of spike protein were quantitatively evaluated in a sample of 230 negative RT-PCR tests for the COVID-19 individuals. The analysis has been done based on an immunological assay using enzyme-linked immunosorbent assay (ELISA). The infection history of the subjects and their families was examined through their medical records.
Our results demonstrated a significant association between a higher titer of IgG and a previous history of the COVID-19 infection (P<0.001). Moreover, the chance of detecting antibodies titer more than 50 AU/ml was 16.99 in these people which was significantly higher than in people without a history of infection pre-vaccination [%95CI: (7.38,39.12), P<0.001].
This result demonstrates that the efficacy of antibody production is related to the previous history of the SARS-CoV-2 infections. Ongoing monitoring of the level of antibody among vaccinated populations will help evaluating the effect of vaccines on humoral immunity status.
测量接种 SARS-CoV-2 刺突蛋白后产生的抗体水平被认为是评估 COVID-19 疫苗有效性的一种策略。
检查伊朗马什哈德不同医院的医护人员在接种第二剂 Sputnik V 后的抗体水平。
在这项研究中，我们招募了 230 名医护人员，用于评估 Gam-COVID-Vac 或 Sputnik V 在马什哈德不同医院接种第二剂后的效果。对 230 名 COVID-19 个体的 RT-PCR 检测阴性样本进行了定量评估，以评估刺突蛋白的抗体水平。该分析是基于使用酶联免疫吸附试验（ELISA）的免疫测定法进行的。通过他们的病历检查了受试者及其家属的感染史。
我们的结果表明，较高的 IgG 滴度与 COVID-19 感染史之间存在显著关联（P<0.001）。此外，这些人检测到抗体滴度超过 50 AU/ml 的几率为 16.99，明显高于接种前无感染史的人（%95CI：（7.38,39.12），P<0.001）。
该结果表明，抗体产生的功效与 SARS-CoV-2 感染的既往史有关。对接种人群的抗体水平进行持续监测将有助于评估疫苗对体液免疫状态的影响。
